Association of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/8933859 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Ahmed Adel Mohamed und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Zagazig University, Zagazig, Egypt, zu.edu.eg. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients undergoing transcatheter aortic valve implantation (TAVI) remain at risk of adverse cardiovascular and renal outcomes despite procedural advancements. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits across various patient populations; however, their role in patients undergoing TAVI remains unclear. This study is aimed at evaluating the association between SGLT2 inhibitor use and clinical outcomes in this population.
Methods
We conducted a systematic review and meta‐analysis comparing SGLT2 inhibitors versus non‐SGLT2 inhibitors or standard care in patients undergoing TAVI. Major databases were searched through March 2026, with Embase updated through June 2026. Pooled analyses were performed using random‐effects models to calculate risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs).
Results
Five studies involving 6111 patients (SGLT2 inhibitors: n = 2933; control: n = 3178) were included. In primary random‐effects models, SGLT2 inhibitors were associated with lower all‐cause mortality (RR 0.68, 95% CI 0.48–0.97, p = 0.03), heart failure (HF) hospitalization (RR 0.62, 95% CI 0.42–0.90, p = 0.01), and major adverse cardiovascular events (RR 0.68, 95% CI 0.48–0.96, p = 0.03). However, in REML/Hartung–Knapp sensitivity analyses, CIs crossed the null for all‐cause mortality, HF hospitalization, MACE, and pooled hazard ratios. Mortality benefits were absent at 6 and 12 months and in the randomized trial but persisted in low left ventricular ejection fraction (RR 0.56, 95% CI 0.35–0.89, p = 0.01). No significant differences occurred in acute kidney injury, urinary tract infections, or echocardiographic parameters.
Conclusion
SGLT2 inhibitor use was associated with lower all‐cause mortality and HF hospitalization after TAVI, but the evidence is limited by observational designs, heterogeneity, and low certainty for several outcomes. Further randomized trials are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Zagazig University, Zagazig, Egypt, zu.edu.eg.
- Faculty of Medicine, Cairo University, Cairo, Egypt, cu.edu.eg.
- Faculty of Medicine, Mansoura University, Al Mansurah, Egypt, mans.edu.eg.
- Faculty of Medicine, Assiut University, Assiut, Egypt, aun.edu.eg.
- Faculty of Medicine, New Ismaila National University, Ismaila, Egypt.
- Faculty of Medicine, South Valley University, Qena, Egypt, svu.edu.eg.
ORCID-Profile: Ahmed Adel Mohamed, Batool Husain Husain, Ghaida Al Shawawreh, Ali Samir Galal, Abdalrahman Salah Shehata, Youssef Ramadan, Osama M Aldeeb, Tasneem Zanati Saeed, Mohammed Dibas
Zitieren
APA
Mohamed, A. A., Husain, B. H., Dali, T. K., Ahmed, M. E., Al Shawawreh, G., Galal, A. S., Moussa, M. A., Hibysh, A. M., Shehata, A. S., Ramadan, Y., Aldeeb, O. M., Saeed, T. Z., & Dibas, M. (2026). Association of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8933859
Vancouver
Mohamed AA, Husain BH, Dali TK, Ahmed ME, Al Shawawreh G, Galal AS, et al. Association of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/8933859
BibTeX
@article{Mohamed2026,
author = {Mohamed, Ahmed Adel and Husain, Batool Husain and Dali, Tammam Khaled and Ahmed, Mostafa Elsayed and Al Shawawreh, Ghaida and Galal, Ali Samir and Moussa, Mahmoud Abdelwahab and Hibysh, Abdallah M and Shehata, Abdalrahman Salah and Ramadan, Youssef and Aldeeb, Osama M and Saeed, Tasneem Zanati and Dibas, Mohammed},
title = {Association of Sodium–Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE‐Assessed Meta‐Analysis},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/8933859}
}
EUVIMED